MEDIA CENTER

September 27, 2022

Ambulero Receives Positive Pre-IND Response from FDA for AMB-301 Treatment of Rare Vascular Disease.  Ambulero, Inc., a Miami, Florida-based spinout from the University of Miami Miller School of Medicine, developing new gene and cell therapies for severe vascular disease, announces it received a positive response from a Type B Pre-IND meeting with the FDA to develop AMB-301 as a treatment for a rare vascular condition called Buerger’s Disease.

For more information

September 8, 2022

Ambulero is a proud corporate acceleration partner under a multi-year CATALYZE grant administered by the National Heart, Lung and Blood Institute (NHLBI). The NHLBI CATALYZE program supports and funds product definition, pre-clinical research and development of technology and transformative platforms. 

For more information: https://lnkd.in/gw3Jcj_5

August 23, 2022

We’ve been invited to present Ambulero at the 12th annual Landmark Investing For Cures Forum taking place September 14-15, 2022. Landmark will bring together family offices, HNW investors, pharma, philanthropic foundations and innovative companies in an invitation only event geared to identifying and promoting new healthcare treatments.


https://lnkd.in/esdbh7hb

August 19 , 2022

We are delighted to announce that we've been selected as a 2022 Fibonacci Finalist by the Cade Museum of Creativity and Innovation (Gainsville, Florida). The Cade Prize is a capstone initiative of the Museum named after Dr. James Robert Cade, the lead inventor of Gatorade. We are proud to receive this important recognition in our home state of Florida.

 

See https://lnkd.in/dD7tiy4W

June 23, 2022

Our co-founders, Omaida C. Velazquez and Zhao-Jun Liu, recently published non-clinical data supporting further development of E-selectin/AAV gene therapy to treat chronic limb ischemia (CLI): a severe blood vessel disease effecting millions of patients. In a relevant animal model, they showed that E-selectin/AAV gene therapy increased vascularity, preserved muscle integrity, unpregulated pro-angiogenic genes and downregulated genes associated with inflammation. Ambulero and the University of Miami are supporting the development of E-selectin/AAV gene therapy to treat CLI and other vascular diseases. 

For more information: https://lnkd.in/g9vdeZEn

 

June 19, 2022

Our CEO Robert L Buchanan will join other biotech executives on 30 June 2022 to discuss licensing case studies from their respective US and European organizations.This is an invitation only event sponsored by the European Innovation Council and SMEs Executive Agency (EISMEA). A goal of the event is to promote licensing best practices using real-life examples. For more information, please contact Dr. Maximilian Siebert at EISMEA. 

For more information: https://lnkd.in/gM3DxHTF

April 20, 2022

Mesenchymal stromal cells (MSCs) have an inherent ability to support healing. Omaida C. Velazquez and Zhao-Jun Liu of the University of Miami Miller School of Medicine have engineered MSCs to express a cell adhesion molecule called E-selectin. We call these cells “supercharged MSCs” because they can repair and regenerate damaged vascular tissue and reduce muscle atrophy in animal models. We are presenting this work on May 24, 2022 at an event entitled “Challenges And Opportunities For Mesenchymal Cells”.  Supercharged MSCs are a promising new cell therapy for testing in future clinical trials. 

For more information, see https://lnkd.in/e7VQ5zi9

April 14, 2022

We are happy to mention that Dr. Zhao-Jun Liu, Chief Scientific Officer of Ambulero Inc. and Associate professor of Surgery at the University of Miami Miller School of Medicine, has been appointed Associate Editor of the journal Frontiers in Oncology. We all wish Dr. Liu the best in his new position on the Editorial Board. 

For more information, see https://lnkd.in/ebwTPfXT

March, 10, 2022

Ambulero will be participating in H.C. Wainwright’s Gene Therapy and Gene Editing Conference taking place on March 30, 2022.  
Robert L. Buchanan, CEO, and Co-Founder will virtually present the company and provide updates on development of its gene therapy platform to treat severe vascular diseases. Ambulero is a first mover in a new field of using a cell adhesion molecule (E-selectin) to improve regeneration of vascular wound beds.  

For more information about the H.C Wainwright conference, see https://hcwevents.com/genetherapy

January 31, 2022

Ambulero’s gene and cell therapy platform uses E-selectin to support healing of vascular wound beds.  In an article published in Frontiers In Cardiovascular Medicine, co-authors Omaida C. Velazquez and Zhao-Jun Liu report that mesenchymal stems cells engineered to express E-selectin (“supercharged” cells) confer improved repurfusion, repair and regeneration in an animal model of Chronic Limb Ischemia. The company is developing supercharged cells as a possible therapeutic option for patients suffering from certain vascular diseases.

See http://journal.frontiersin.org/article/10.3389/fcvm.2021.826687/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Cardiovascular_Medicine&id=826687

January 30, 2022

Our Chief Medical Officer (Dr. Omaida Velazquez) and Chief Scientific Officer (Dr. Zhao-Jun Liu) co-authored a recent review article in Therapeutic Advances In Rare Disease describing challenges and advances in the treatment of Buerger’s Disease: a rare vasculitis that can lead to amputation. The review highlights new potential treatment options including Ambulero’s gene therapy approach to support therapeutic angiogenesis by providing E-selectin

See https://lnkd.in/gZFnXexk

December 16, 2021

Ambulero Makes Cover of Brainstroms! --The Magazine of the University of Miami’s
Miller School of Medicine 

We are honored to be on the cover of Brainstorms! The Ambulero article highlights important guidance and support provided by Dr. Norma Sue Kenyon (UM’s Vice Provost For Innovation), U Innovation, the Wallace H. Coulter Foundation and UM’s Office of Technology Transfer that led to the founding of Ambulero.  A special thanks to our Chief Medical Officer (Omaida C. Velazquez) and Chief Scientific Officer (Zhao-Jun Liu) for over a decade of groundbreaking research that is at the heart of our first-in-class pipeline of gene and cell therapy products for treating severe vascular diseases that can lead to amputation. 

See https://magazine.med.miami.edu/brainstorms

November 11, 2021

Our Chief Medical Officer, Dr. Omaida C. Velazquez, was an invited speaker at the George Johnson Jr. Distinguished Professor of Surgery Grand Rounds of the University of North Carolina School of Medicine. Dr. Velazquez talked about her professional journey as well as the genesis of Ambulero: a cell and gene therapy spinout of the University of Miami's Miller School of Medicine dedicated to treating severe vascular diseases. 

See https://uncch.hosted.panopto.com/Panopto/Pages/Embed.aspx?id=9a0f67c3-ae2d-4f92-9ac8-ad3b00e9f8fe 

October 27, 2021

Ambulero’s Chief Scientific Officer Appointed to Review Editor
We are pleased to announce that our Chief Scientific Officer, Zhao-Jun Liu, MD, PhD, has been appointed a Review Editor of the following scientific journals:  Frontiers in Cardiovascular Therapeutics and Frontiers in Cardiovascular Medicine.  Dr. Liu is also an Associate Professor at the University of Miami’s Miller School of Medicine with an appointment in the DeWitt Daughtry Family Department of Surgery.  We wish Dr. Liu all the best in his new editorial roles.

 

October 19, 2021

Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation. 

See https://www.globenewswire.com/news-release/2021/10/19/2316659/0/en/Ambulero-s-Gene-Therapy-Candidate-AMB-301-Granted-US-Orphan-Drug-Designation-For-Treatment-of-Severe-Vascular-Disease.html

September 29, 2021

Our Chief Medical Officer, Dr. Omaida C. Velazquez, was recently interviewed by the Florida 24 Network; a statewide news channel. She described her journey to become the first Latina in the United States to chair a department of surgery. 

See https://lnkd.in/dCm8DNai

September 14, 2021

A big congratulations to our Chief Medical Officer, Dr. Omaida C. Velazquez, on being honored as the Latina Pioneer of the Year at the 20th Annual Hispanic Women of Distinction Charity Award held in Davie, Florida.
See https://lnkd.in/dQQc9sdj

August 31, 2021

We are very happy to see Drs. Omaida C. Velazquez and Zhao-Jun Liu publish a paper describing the improvement of gangrene, revascularization and limb function in mice using an E-selectin/AAV gene therapy
See  https://lnkd.in/d_kace5i

July 27, 2021

Ambulero is delighted to receive a Notice of Allowance from the United States Patent & Trademark Office (USPTO) for the name “Ambulero”.  Please see the USPTO website for more information: See https://www.uspto.gov

April 28, 2021

Our Chief Medical Officer, Dr. Omaida C. Velazquez, was honored by the University of California, San Francisco (UCSF) with the 29th Robert W. Binkley Visiting Professorship.  She gave a lecture entitled “Restoration of Healing in Ischemic Tissues Using Gene and Cell Therapies:  E-Selectin, an Emerging Vascular Regenerative Platform”.

March 1, 2021

Dr. Khemraj Hirani appointed as Chief Regulatory Officer of Ambulero.

“Raj brings tremendous experience to our cell and gene therapy treatment platforms for treating vascular disease. We are very fortunate to have him”, said Robert L. Buchanan, co-founder and Chief Executive Officer of Ambulero.

Dr. Hirani is a recognized subject matter expert on FDA and CFR regulations related to clinical trials.  He holds key appointments at the University of Miami, Miller School of Medicine including Director, Regulatory Affairs and Quality Assurance, Diabetes Research Institute and Associate Vice Chair for Research and Regulatory Compliance, Department of Medicine.

February 25, 2021

Dr. Omaida C. Velazquez, Chief Medical Officer of Ambulero and Professor and Chair of DeWitt Daughty Family Department of Surgery at the University of Miami, Miller Medical School, discussed the potential of stem cells to regrow vascular tissue and avoid arterial disease in a series called Inside Our Labs: Innovations in Heart Health.
See: https://www.youtube.com/watch?v=sOkBKJSXFC0

February 15, 2021

Ambulero selected as a top therapeutic start-up to follow in 2021.
See https://startupill.com/these-are-the-top-101-therapeutics-startups-to-follow-in-2021

January 25, 2021

Ambulero Raises Up To $5.5M From Orphinic Scientific And Forms European Subsidiary To Advance Rare Vascular Disease Program. See: 
https://www.globenewswire.com/news-release/2021/01/26/2163930/0/en/Ambulero-Raises-Up-To-5-5-Million-from-Orphinic-Scientific.html

 

January 11, 2021

Ambulero Attends Biotech Showcase Digital Investor and Partnering Conference.  
See: www.informaconnect.com/biotech-showcase

 

January 6, 2021

Ambulero Attends Bio Partnering at JPM.  
See https://www.bio.org/events/bio-partnering-jpm

 

November 12, 2020

Miami, FL- Robert Buchanan will present Ambulero at the U Innovation Concept
to Commercialization Series.  To register, please visit: 
https://miami.zoom.us/webinar/register/WN_t4kTLkqjThi3tGWClaAO_A

June 4, 2020

Washington, DC- Ambulero, Inc will be attending BIO Digital from June 8-12, 2020.  For more information, please see www.bio.org.

June 2, 2020

Boston, MA -  Ambulero, Inc. Will be attending Digital RESI from June 8-10, 2020.  For more information, please see www.resiconference.com.

April 23, 2020

Boston, MA - Ambulero, Inc. will be attending Digital RESI from April 29-30, 2020.  For more information about the event and to learn more about the company, please see www.resiconference.com.

April 6, 2020

Miami, Florida - Ambulero, Inc. is pleased to announce the appointment of Dr. Bruce Patsner, M.D., J.D., M.B.A as its FDA regulatory advisor.

“I am delighted to see Bruce join our company as our FDA advisor. His deep expertise in many areas of interest will help guide efforts to bring our therapeutics forward to treat serious vascular diseases” said Robert L. Buchanan, co-founder and CEO of Ambulero.

January 17, 2020

Miami, Florida - Ambulero, Inc. is pleased to announce that Dr. Omaida C. Velazquez (Chief Medical Officer) will be attending the World Stem Cell Summit to be held January 21-24 at the Hyatt Regency in Miami, Florida.

January 10, 2020

Miami, Florida - Ambulero, Inc. is pleased to announce that Dr. Carlton Anderson (COO) and Randy Berholtz (Chairman of the Board) will be attending the J.P. Morgan Healthcare Conference in San Francisco, CA on January 13-16, 2020.

December 12, 2019

Miami, Florida - Ambulero, Inc., a pre-clinical stage regenerative medicines company using gene and cell therapy approaches to treat vascular disease, today announced the appointment of Dr. Greg, Landry, Professor of Surgery, Division of Vascular Surgery, School of Medicine, Oregon Health & Sciences University, as Chair of the Scientific Advisory Board.  

 

Dr. Landry comes to Ambulero as head of OHSU’s division of vascular surgery with clinical expertise in upper arterial and venous disease, abdominal aortic aneurysms, cerebrovascular disease, hemodialysis access and renovascular and visceral arterial disease. 

 

“I am delighted to have Greg chair our Scientific Advisory Board and to provide the company with advice and guidance in our clinical trial designs for treating vascular disease” said Robert L. Buchanan, co-founder and CEO of Ambulero.

 

Other members of the Scientific Advisory Board are to be announced.

November 1, 2019

Miami, Florida - Ambulero Inc., a pre-clinical stage regenerative medicines company focused on developing next-generation cell and gene therapies announced an exclusive licensing agreement with the University of Miami for intellectual property relating to the development and commercialization of cell and gene therapies for ischemic diseases.

 

Under the terms of the agreement, Ambulero is granted exclusive rights to gene and cell therapy technologies for introducing the cell adhesion molecule E-selectin into tissues damaged by vascular disease. University of Miami researchers have shown in relevant animal models that administration of the adhesion molecule can enhance blood flow and wound healing.

 

Pursuant to the terms of the exclusive license agreement, the University of Miami will become a shareholder in the company and will receive an upfront payment and certain clinical, regulatory, and sales milestone payments, as well as royalties on net sales of products covered by the license.